Pediatric AMLs with mixed lineage leukemia (MLL) rearrangements (or KMT2A, lysine (K)-specific methyltransferase 2A) represent about 20% of all pediatric AML patients [3]. The gene discussed is KMT2A; the disease is leukemia.